Provided by Tiger Trade Technology Pte. Ltd.

United Therapeutics

506.82
+8.851.78%
Pre-market: 506.00-0.8200-0.16%08:00 EDT
Volume:500.11K
Turnover:251.89M
Market Cap:21.74B
PE:18.13
High:509.53
Open:502.75
Low:492.90
Close:497.97
52wk High:609.35
52wk Low:395.00
Shares:42.89M
Float Shares:39.35M
Volume Ratio:0.75
T/O Rate:1.27%
Dividend:- -
Dividend Rate:- -
EPS(TTM):27.95
EPS(LYR):27.86
ROE:19.31%
ROA:11.61%
PB:3.40
PE(LYR):18.19

Loading ...

United Therapeutics' Q2 Tyvaso Miss Reflects Competition; IPF Outreach Set to Expand, Morgan Stanley Says

MT Newswires Live
·
Aug 06

United Therapeutics Corp. : Wells Fargo Cuts Target Price to $700 from $738

THOMSON REUTERS
·
Aug 06

Morgan Stanley Adjusts PT on United Therapeutics to $515 From $516, Maintains Equalweight Rating

MT Newswires Live
·
Aug 06

United Therapeutics Balances Tyvaso Woes With Pipeline Wins

TIPRANKS
·
Aug 06

Zevra Therapeutics Q2 Revenue Rises 53% on Miplyffa Sales

Reuters
·
Aug 06

Biopharma Firm MannKind Q2 Posts Net Loss on Product Launch Expenses

Reuters
·
Aug 06

Vanda Pharmaceuticals Q2 Loss Widens on Lower Sales, Higher Costs

Reuters
·
Aug 06

United Therapeutics Corporation Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 05

United Therapeutics Q2 Net Income Rises, Revenue Falls

MT Newswires Live
·
Aug 05

United Therapeutics Q2 2026 earnings: Lower taxes lift EPS as revenue slips

TradingKey
·
Aug 05

United Therapeutics Q2 Revenue Misses Estimates on Ebulized Tyvaso Weakness

Reuters
·
Aug 05

Stock Track | United Therapeutics Plunges 7.46% in Pre-market After Q2 Revenue Misses Estimates

Stock Track
·
Aug 05

Earnings Flash (UTHR) United Therapeutics Posts Q2 EPS $7.27, vs. FactSet Est of $6.86

MT Newswires Live
·
Aug 05

United Therapeutics Q2 Revenue USD 783.3 Million Vs. IBES Estimate USD 805.6 Million

Reuters
·
Aug 05

United Therapeutics Q2 EPS $7.27 Beats $6.88 Estimate, Sales $783.300M Miss $805.645M Estimate

Benzinga Earnings
·
Aug 05

United Therapeutics Q2 EPS USD 7.27

THOMSON REUTERS
·
Aug 05

United Therapeutics Corporation Reports Second Quarter 2026 Financial Results

THOMSON REUTERS
·
Aug 05

United Therapeutics Chairperson, CEO Martine Rothblatt Reports Disposal of 9,500 Common Shares for $4.9 Million

Reuters
·
Aug 05

United Therapeutics CEO Martine Rothblatt Disposes of Common Shares Worth $4.96 Million

Reuters
·
Jul 30

United Therapeutics Says FDA Reviews Ralinepag NDA for Pulmonary Arterial Hypertension

Reuters
·
Jul 29